This higher expression of CCNB2 as shown by the results of promoter methylation and poor prognosis obtained from the survival analysis demonstrated the efficacy of this gene to be a suitable candidate for the prediction, diagnosis and treatment of HCC. This evidence concerns the gene CCNB2 and hepatocellular carcinoma.